Research status and application prospect of a novel immune checkpoint TIGIT in the immunotherapy of multiple myeloma
10.3760/cma.j.cn371439-20221024-00025
- VernacularTitle:新型免疫检查点TIGIT在多发性骨髓瘤免疫治疗中的研究现状与应用前景
- Author:
Yuxiao ZHANG
1
;
Liansheng ZHANG
;
Lijuan LI
Author Information
1. 兰州大学第二医院血液科，兰州 730000
- Keywords:
Multiple myeloma;
Immunotherapy;
TIGIT
- From:
Journal of International Oncology
2023;50(2):122-125
- CountryChina
- Language:Chinese
-
Abstract:
T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is a new immune checkpoint protein. Studies have shown that TIGIT can cause dysfunction of immune cells, weaken the anti-tumor effect, thus leading to tumor immune tolerance and immune escape. Blocking TIGIT can reverse immune cell failure and exert anti-tumor effect, which is expected to become a new therapeutic target for multiple myeloma.
